Anticardiolipin Antibodies and Obstructive Vascular Events

抗心磷脂抗体和阻塞性血管事件

• 批准号: 11470122
• 负责人: KOIKE Takao
• 金额: $ 9.09万
• 依托单位: HOKAIDO UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B).
• 财政年份: 1999
• 资助国家: 日本
• 起止时间: 1999 至 2000
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-11470122/
• 关键词: antiphospholipid antibodies; antiphosphlipid syndrome; anticardiolipin anibodies; lupus anticoagulant; thrombosis; arteriosclerosis; β2GPI; β2GPI-deficiency; 流産; エピトープ; スシドメイン; ランダムペプチドライブラリー; β2グリコプロテインI; β2グリコプロテイン; 立体構造; エピトープマッピング; ペプチ

Arterial and/or venous thrombosis, recurrent fetal loss and thrombocytopenia are frequently found in patients with antiphospholipid antibodies (anticardiolipin antibodies (aCL) and lupus anticoagulant (LA)). The term antiphospholipid syndrome (APS) has been used to define this set of pathologic features.. Recent evidence suggested that antiphospholipid antibodies may have contributed to the formation of atherosclerotic lesions. In SLE less than 45 years of age, myocardial infarction has been recognized as a major cause of mortality.I have reported that aCL found in patients with APS are not simply directed to the CL structure, but require the presence of β2-glycoprotein I (β2GPI) for bindng and that the epitopes is expressed by conformational changes occurring when β2GPI interacts with an oxygen-substituted solid surface.I performed the reserch project, entitled "Anticardiolipin Antibodies and Obstructive Vascular Events" from 1999 to 2001 and obtained the following results ;1) Presence of anticardiolipin antibodies is risk factors for thrombus formation and atherosclerosis.2) We discovered the β2GPI-deficient families and named β2GPI-Sapporo.3) Genetic polymorphysm of β2GPI is influenced on the epitope formation of aCL and on the development of APS

动脉和/或静脉血栓形成、反复流产和血小板减少症常见于抗磷脂抗体（抗心磷脂抗体（aCL）和狼疮抗凝物（LA））患者。术语抗磷脂综合征（APS）已被用来定义这组病理。特征.. 最近的证据表明，抗磷脂抗体可能有助于 45 岁以下的 SLE 形成动脉粥样硬化病变。心肌梗塞已被认为是导致死亡的主要原因。我曾报道过，在 APS 患者中发现的 aCL 并非简单地针对 CL 结构，而是需要存在 β2-糖蛋白 I (β2GPI) 才能结合，并且表位为通过 β2GPI 与氧取代的固体表面相互作用时发生的构象变化来表达。我进行了题为“抗心磷脂抗体和阻塞性血管事件”的研究项目1999年至2001年，获得以下结果；1）抗心磷脂抗体的存在是血栓形成和动脉粥样硬化的危险因素。2）我们发现了β2GPI缺陷家族，并将其命名为β2GPI-Sapporo。3）β2GPI的遗传多态性受表位影响aCL 的形成和 APS 的发展

项目成果

小池隆夫: "β2-blycoprotein I deficiency : prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis."Atherosclerosis.. 152. 337-346 (2000)

Takao Koike：“β2-糖蛋白 I 缺乏症：患病率、遗传背景以及对血浆脂蛋白代谢和止血的影响。”动脉粥样硬化.. 152. 337-346 (2000)

小池隆夫: "Anticardiolipin Antibody, Thrombosis and Atherosclerosis."The Decade of Autoimmunity.. 9 (1999)

Takao Koike：“抗心磷脂抗体、血栓形成和动脉粥样硬化。”自身免疫的十年.. 9 (1999)

小池隆夫: "Heterogeneous behavior anti-β2-glycoprotein."J.Rheumatol.. 72:2. 391-397 (2000)

Takao Koike：“异质行为抗 β2-糖蛋白”。J.Rheumatol.. 72:2 (2000)。

小池隆夫: "Lytic epstein-barr virus infection in the synovial tissue of patients with rheumatoid arthritis."Arthritis.Rheum.. 43:6. 1218-1225 (2000)

Takao Koike：“类风湿性关节炎患者滑膜组织中的裂解性 epstein-barr 病毒感染。”Arthritis.Rheum.. 1218-1225 (2000)。

Koike T: "Anticardiolipin Antibody, Thrombosis and Atherosclerosis. Y.Shoenfeld ed.in The Decade of Autoimmunity."Elsevier Science B.V.. 9 (1999)

Koike T：“抗心磷脂抗体、血栓形成和动脉粥样硬化。Y.Shoenfeld 编辑，《自身免疫的十年》。”Elsevier Science B.V.. 9 (1999)